Akoya Biosciences (AKYA) Scheduled to Post Quarterly Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA) is set to post its quarterly earnings results after the market closes on Monday, May 13th. Analysts expect Akoya Biosciences to post earnings of ($0.30) per share for the quarter. Akoya Biosciences has set its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Akoya Biosciences (NASDAQ:AKYA) last released its quarterly earnings results on Monday, March 4th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.12 million. Akoya Biosciences had a negative net margin of 65.53% and a negative return on equity of 110.24%. During the same quarter in the previous year, the company earned ($0.50) EPS. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Price Performance

AKYA stock opened at $4.04 on Monday. Akoya Biosciences has a 52-week low of $3.04 and a 52-week high of $8.80. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 1.41. The stock has a market cap of $199.50 million, a price-to-earnings ratio of -2.73 and a beta of 1.52. The business has a fifty day moving average of $4.58 and a two-hundred day moving average of $4.65.

Insider Buying and Selling

In other Akoya Biosciences news, CEO Brian Mckelligon sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $4.94, for a total value of $37,050.00. Following the completion of the transaction, the chief executive officer now owns 224,368 shares of the company’s stock, valued at approximately $1,108,377.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 8.50% of the stock is owned by insiders.

Analyst Ratings Changes

AKYA has been the topic of several research analyst reports. UBS Group boosted their price objective on shares of Akoya Biosciences from $7.00 to $7.50 and gave the company a “buy” rating in a report on Tuesday, March 5th. JPMorgan Chase & Co. lowered their price objective on shares of Akoya Biosciences from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, March 6th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 target price on shares of Akoya Biosciences in a research report on Tuesday, March 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Akoya Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $9.07.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.